The new research tends to help lower the spread of HIV virus. The team of researchers from the Institute of the University of New South Wales led by the Head of HIV epidemiology and prevention, Andrew Grulich, has developed a new antiviral pill that is able to reduce the HIV cases. This breakthrough may accelerate the process of trying to put an end to the AIDS epidemic.
The blue pill named “Truvada” has been designed to target the HIV virus and bring about a huge decline in the AIDS-causing viruses. The occurrence of the disease among the gay and bisexual men has also come down to a great extent. The US and other countries plan to pave a new way so as to reduce the transmission of the virus by educating the populace using pre-exposure prophylaxis (PrEP) treatment method. The UN member states plan to put a total end to the epidemic by the end of 2030. A fall of about 1.8 Million in the HIV infection on a worldwide level had been seen in 2017. The highly costive-effective method PrEP shows a great efficacy among the population in the US. However, the policymakers have a little reluctance in rolling funds for the new treatment method owing to the population impact.
The researchers have combined the drugs disoproxil, emtricitabine, and tenofovir in different doses and made a generic version of Truvada for the PrEP treatment. This pill made by Teva Pharmaceutical Industries Ltd., Mylan NV, and Cipla Ltd. is currently being tried to be made available for the people at a cheaper price. The US has shown a great improvement in controlling the AIDS-causing virus by use of PrEP, according to Chief Executive Officer John F. Milligan of Gilead Sciences Inc. Dr. Dan H. Barouch belonging to the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, Boston has developed a mosaic HIV vaccine using different parts of the virus so as to help trigger a great immune response in the patients. This novel vaccine is expected to outdo the others currently publicized in the market.